Buscar
Mostrando ítems 1-10 de 76
Osteonecrosis of the jaw in patient with denosumab therapy
(E-Century Publishing Corporation, 2014)
Pharmacotherapy of Bone Loss in Postmenopausal Women: Focus on Denosumab
(SAGE PublicationsGrupo Endocrinología y Metabolismo – GEMEstados Unidos, 2022)
Estudo de métodos físico-químicos e biológico para caracterização e avaliação do anticorpo monoclonal recombinante denosumabe
(Universidade Federal de Santa MariaBrasilAnálises Clínicas e ToxicológicasUFSMPrograma de Pós-Graduação em Ciências FarmacêuticasCentro de Ciências da Saúde, 2021-10-21)
Denosumab (DmAb) is monoclonal antibody (mAb) that inhibits proliferation and activity of osteoclasts cells, that is commercially available in Brazil as Prolia® and Xgeva®, for treatment of bone diseases. Structurally, it ...
Estudo de métodos cromatográficos e ensaio biológico para avaliação do anticorpo monoclonal denosumabe
(Universidade Federal de Santa MariaBrasilAnálises Clínicas e ToxicológicasUFSMPrograma de Pós-Graduação em Ciências FarmacêuticasCentro de Ciências da Saúde, 2017-07-27)
Denosumab (DmAb) is a fully human monoclonal antibody that inhibits osteoclast formation, function and survival, reducing bone turnover and resorption. Structurally, it is a fully human immunoglobulin G2, yielding a molecular ...
Avaliação do cálcio, fósforo, paratormônio e fosfatase alcalina séricos em ratos sob efeito de medicamentos antirreabsortivos e exodontia
(Universidade Federal de Santa MariaBrasilOdontologiaUFSMPrograma de Pós-Graduação em Ciências OdontológicasCentro de Ciências da Saúde, 2021-09-16)
Medication-related osteonecrosis of the jaw (MRONJ) is a severe and debilitating bone pathology whose etiopathogenesis is not fully understood, and there is still no effective standard treatment for the condition. Since ...
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
(American Society for Bone and Mineral Research, 2012-03)
Dual-energy X-ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture risk in untreated patients. However, previous patient-level studies suggest that BMD changes explain little of the fracture ...